GSK plc (GSK)
| Market Cap | 80.37B |
| Revenue (ttm) | 43.34B |
| Net Income (ttm) | 4.69B |
| Shares Out | 4.05B |
| EPS (ttm) | 1.13 |
| PE Ratio | 35.65 |
| Forward PE | 9.26 |
| Dividend | $1.62 (4.01%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 3,928,735 |
| Open | 40.28 |
| Previous Close | 40.05 |
| Day's Range | 40.13 - 40.53 |
| 52-Week Range | 31.72 - 43.14 |
| Beta | 0.29 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Oct 29, 2025 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2024, GSK's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial numbers in GBP Financial StatementsNews
UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit
British pharmaceutical giant GSK committed to investing at least $30 billion in U.S. research and developing and manufacturing over the next five years.
GSK and Eli Lilly are the latest multinational drugmakers to unveil plans to build more U.S. manufacturing plants and other operations, moves aimed partly at mitigating the threat of tariffs
GSK and Eli Lilly are the latest to unveil plans to add to manufacturing and increase other operations in America.
GSK plans $30 billion US investment as pharma tariff threat looms
GSK said on Wednesday it plans to invest $30 billion in research and development and supply chain infrastructure in the United States over the next five years, after U.S. President Donald Trump arrive...
GSK Says It Will Spend $30B on U.S. Manufacturing and R&D
The U.K.-based firm and other drugmakers are seeking to avoid tariffs on drugs imported into the U.S.
Dividend Income Summary: Lanny's July 2025 Summary
In July, we (my wife and I) received a dividend income total of $4,161.64. My other two Vanguard ETFs – S&P 500 (VOO) and Dividend Appreciation ETF (VIG) - both paid in July. We had a solid increase m...
US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says
The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, ac...
Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?
Wave Life Sciences Ltd. WVE stock is trading lower on Wednesday after the company shared data from the ongoing Phase 1b/2a RestorAATion-2 Trial of WVE-006 in alpha-1 antitrypsin deficiency.
Dynavax's shingles vaccine shows similar immune response to GSK's shot in study
Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in early-to-mid-s...
GSK's antibiotic drug gepotidacin gets priority review by FDA
British drugmaker GSK said on Monday its supplemental new drug application for antibiotic drug gepotidacin has been accepted for priority review by the U.S. Food and Drug Administration for the oral t...
GSK to Receive $370 Million in U.S. Patent Litigation Settlement
The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination mRNA vaccine products made by BioNTech and Pfizer.
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.
President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
Trump pressures 17 pharma CEOs to cut US drug prices
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...
Trump posts letters to 17 pharmaceutical companies about drug prices
CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont...
GSK plc (GSK) Q2 2025 Earnings Call Transcript
GSK plc (NYSE:GSK) Q2 2025 Earnings Conference Call July 30, 2025 7:00 AM ET Company Participants Deborah Jayne Waterhouse - CEO of ViiV Healthcare & President of Global Health Emma Natasha Walmsley ...
GSK CEO: Innovation is the secret to bringing down cost of overall healthcare
Emma Walmsley, GSK CEO, joins CNBC's 'Squawk on the Street' to discuss the company's most recent earnings, innovation pipeline, the potential impact of tariffs on pharmaceuticals, and much more.
GSK in talks with Trump administration on U.S. drug pricing, CEO says
British drugmaker GSK said on Wednesday it is in talks with the Trump administration about ways to lower U.S. drug costs, becoming the latest pharmaceutical company to acknowledge action under pressur...
GSK expects annual sales and profit at top end of forecast range
British drugmaker GSK said on Wednesday it expects to report annual sales and profit towards the top end of its forecast range, adding that its outlook includes the impact of tariffs in place so far a...
GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval
GSK's diversified portfolio and strong HIV/specialty medicines offer stability, but growth prospects remain modest amid stiff competition and legal overhangs. Despite a robust pipeline and management'...
Jiangsu Hengrui grants GSK global rights to drug portfolio in $500 million deal
China's Jiangsu Hengrui Pharmaceuticals said on Monday it has agreed to license the global rights of its HRS-9821 drug and 11 other programmes to GlaxoSmithKline Intellectual Property (GSK) for $500 m...
Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD Additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK fo...
GSK's blood cancer drug gets EU approval for multiple myeloma
British drugmaker GSK said on Thursday the European Union has approved the company's blood cancer drug Blenrep for the treatment of relapsed or refractory multiple myeloma.
GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults
PHILADELPHIA--(BUSINESS WIRE)-- #Adult--GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults.